Theralase Technologies (CVE:TLT) Shares Down 3.6% - Here's Why

Key Points

• Shares down 3.6% — Theralase stock fell to C$0.27 on Friday with about 197,449 shares traded, roughly 3% above its average daily volume.
• Clinical-stage pharmaceutical — The company develops light-activated photodynamic compounds and markets super-pulsed laser technology for cancer, infectious agents, and chronic knee and musculoskeletal conditions.
• Valuation and liquidity signals — Market cap is C$71.53M with a negative P/E (-15.00); key ratios include a current ratio of 0.83, quick ratio of 3.40, debt-to-equity of 29.26, and 50-/200-day moving averages of C$0.28/C$0.22.

Theralase Technologies Inc. (CVE:TLT - )'s stock price dropped 3.6% during mid-day trading on Friday . The stock traded as low as C$0.27 and last traded at C$0.27. Approximately 197,449 shares changed hands during trading, an increase of 3% from the average daily volume of 192,614 shares. The stock had previously closed at C$0.28.

Theralase Technologies Price Performance

The firm has a 50 day moving average of C$0.28 and a 200-day moving average of C$0.22. The company has a market cap of C$71.53 million, a P/E ratio of -15.00 and a beta of -0.29. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.